AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal

 
• By Jo Shorthouse

AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease. 

Astronaut
Going where no big pharma has gone before, AbbVie’s collab with Mission is the first of its kind • Source: Shutterstock

More from R&D

More from Scrip